Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML

Blood. 2023 Oct 12;142(15):1323-1327. doi: 10.1182/blood.2023020102.

Authors

Jundan Xie¹, Xiebing Bao¹, Sheng-Li Xue¹, Hongjie Shen¹, Jiannong Cen¹, Li Yao¹, Jinlan Pan¹, Mingqing Zhu¹, Dandan Liu¹, Xiaohui Hu², Qian Wu¹, Jingren Zhang¹, Haiping Dai¹, Yanglin Cao¹, Xuefeng He², Xiaowen Tang¹, Ai-Ning Sun¹, Ying Wang¹, Jianhong Fu¹, Huiying Qiu¹, Xiaofei Yang¹, Suning Chen¹, Depei Wu¹

Affiliations

¹ National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
² Suzhou Hongci Hospital, Suzhou, China.

PMID: 37478399
DOI: 10.1182/blood.2023020102

No abstract available

Publication types

Letter

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Azacitidine* / adverse effects
Bridged Bicyclo Compounds, Heterocyclic / adverse effects
Decitabine / therapeutic use
Humans
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / drug therapy
Sulfonamides*

Substances

Decitabine
venetoclax
Azacitidine
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides